Schedule I - Condensed Financial Information of Registrant - Narrative (Details)			1 Months Ended						12 Months Ended			48 Months Ended
	Feb. 10, 2023 $ / shares	Jan. 30, 2013 USD ($)	Jan. 31, 2023 USD ($) $ / shares shares	May 31, 2021 USD ($) shares	Feb. 28, 2019 USD ($) day $ / shares shares	Feb. 28, 2018 USD ($) $ / shares	Nov. 30, 2015 USD ($)	Jan. 31, 2013	Dec. 31, 2022 USD ($) day shares	Dec. 31, 2021 USD ($) shares	Dec. 31, 2020 USD ($)	Dec. 31, 2016 USD ($) shares	Jan. 01, 2022 USD ($)	Jan. 01, 2021 USD ($)	Dec. 31, 2019 USD ($)	Feb. 01, 2019 USD ($)
Debt Instrument [Line Items]
Investments									$ 28,080,000	$ 10,729,000
Goodwill									595,851,000	520,601,000			$ 710,408,000	$ 718,625,000
Converted debt amount									0	68,775,000	$ 0
Loss on conversion of the 2025 Notes									0	11,111,000	0
Equity									1,561,648,000	1,685,126,000	1,671,551,000				$ 1,614,759,000
Remaining principal									256,251,000	205,271,000
Credit line capacity									105,348,000
Retained Earnings
Debt Instrument [Line Items]
Equity									(1,822,923,000)	(1,511,976,000)	(1,481,833,000)				(1,511,077,000)
Additional Paid-in Capital
Debt Instrument [Line Items]
Equity									3,421,872,000	3,222,487,000	3,152,694,000				3,142,993,000
Cumulative Effect, Period of Adoption, Adjustment
Debt Instrument [Line Items]
Equity										(21,642,000)			21,600,000		(1,342,000)
Cumulative Effect, Period of Adoption, Adjustment | Retained Earnings
Debt Instrument [Line Items]
Equity										17,458,000			17,500,000		$ (1,342,000)
Cumulative Effect, Period of Adoption, Adjustment | Additional Paid-in Capital
Debt Instrument [Line Items]
Equity										(39,100,000)			(39,100,000)
Convertible Debt
Debt Instrument [Line Items]
Interest rate of notes payable					4.50%
Senior Notes
Debt Instrument [Line Items]
Remaining principal									142,096,000	119,360,000
Senior Notes | Cumulative Effect, Period of Adoption, Adjustment | Accounting Standards Update 2020-06
Debt Instrument [Line Items]
Remaining principal										21,642,000
Line of Credit
Debt Instrument [Line Items]
Remaining principal									$ 13,740,000	13,672,000
Convertible Senior Notes Due 2025 | Convertible Debt
Debt Instrument [Line Items]
Debt face amount					$ 200,000,000
Conversion ratio					0.2367424
Conversion price (in dollars per share) | $ / shares					$ 4.22
Converted debt amount				$ 55,400,000
Shares issued on converted debt (in shares) | shares				19,051,270
Loss on conversion of the 2025 Notes										$ 11,100,000
Shares issuable under debt agreement (in shares) | shares					30,000,000
Decrease in shares issuable under debt agreement (in shares) | shares				8,105,175
Outstanding shares on converted debt (in shares) | shares									21,144,825	21,144,825
Proceeds one-time nominal fee									$ 300,000
Remaining principal									$ 142,096,000	$ 119,360,000
Convertible Senior Notes Due 2025 | Convertible Debt | Redemption period one
Debt Instrument [Line Items]
Convertible debt, stock price trigger threshold (as a percent)					130.00%
Equivalent redemption price (as a percent)					100.00%
Convertible Senior Notes Due 2025 | Convertible Debt | Redemption period two
Debt Instrument [Line Items]
Convertible debt, stock price trigger threshold (as a percent)					98.00%
Convertible Senior Notes Due 2025 | Convertible Debt | Redemption period three
Debt Instrument [Line Items]
Convertible debt, stock price trigger threshold (as a percent)									130.00%
Equivalent redemption price (as a percent)									100.00%
Convertible Senior Notes Due 2025 | Convertible Debt | Minimum | Redemption period one
Debt Instrument [Line Items]
Number of trading days | day					20
Convertible Senior Notes Due 2025 | Convertible Debt | Minimum | Redemption period two
Debt Instrument [Line Items]
Number of trading days | day					5
Convertible Senior Notes Due 2025 | Convertible Debt | Minimum | Redemption period three
Debt Instrument [Line Items]
Number of trading days | day									20
Convertible Senior Notes Due 2025 | Convertible Debt | Maximum | Redemption period one
Debt Instrument [Line Items]
Number of consecutive trading days applicable conversion price | day					30
Convertible Senior Notes Due 2025 | Convertible Debt | Maximum | Redemption period two
Debt Instrument [Line Items]
Number of consecutive trading days applicable conversion price | day					5
Convertible Senior Notes Due 2025 | Convertible Debt | Maximum | Redemption period three
Debt Instrument [Line Items]
Number of consecutive trading days applicable conversion price | day									30
Notes Due February 1, 2033 | Convertible Debt
Debt Instrument [Line Items]
Converted debt amount												$ 143,200,000
Notes Due February 1, 2033 | Convertible Debt | Equity securities
Debt Instrument [Line Items]
Shares issued on converted debt (in shares) | shares												21,539,873
Notes Due February 1, 2033 | Senior Notes
Debt Instrument [Line Items]
Debt face amount		$ 175,000,000
Interest rate of notes payable		3.00%
Equivalent redemption price (as a percent)		100.00%
Notes Due February 1, 2033 | Notes
Debt Instrument [Line Items]
Equivalent redemption price (as a percent)								100.00%
Debt repurchase amount																$ 28,800,000
Remaining principal									$ 3,050,000	3,050,000						3,000,000
New Credit Agreement | Line of Credit | Revolving Credit Facility
Debt Instrument [Line Items]
Remaining principal									18,080,000	0
Credit line capacity							$ 75,000,000
Remaining borrowing capacity									16,800,000
Long-term line of credit, noncurrent									18,100,000	0
New Credit Agreement | Line of Credit | Revolving Credit Facility | 50% Or More Of Revolving Commitment
Debt Instrument [Line Items]
Commitment fee (as a percent)							0.375%
New Credit Agreement | Line of Credit | Revolving Credit Facility | Less Than or Equal To 50% Of Revolving Commitment
Debt Instrument [Line Items]
Commitment fee (as a percent)							0.25%
New Credit Agreement | Line of Credit | Revolving Credit Facility | LIBOR
Debt Instrument [Line Items]
Basis spread on variable rate (as a percent)							2.50%
New Credit Agreement | Line of Credit | Revolving Credit Facility | LIBOR, First 12 Months
Debt Instrument [Line Items]
Basis spread on variable rate (as a percent)							0.75%
New Credit Agreement | Line of Credit | Revolving Credit Facility | LIBOR, First 12 Months, Adjusted for Eurocurrency Liabilities
Debt Instrument [Line Items]
Basis spread on variable rate (as a percent)							1.75%
New Credit Agreement | Line of Credit | Swingline
Debt Instrument [Line Items]
Credit line capacity							$ 20,000,000
New Credit Agreement | Line of Credit | Letter of Credit
Debt Instrument [Line Items]
Credit line capacity							20,000,000
5% Convertible Notes | Convertible Debt
Debt Instrument [Line Items]
Debt face amount						$ 55,000,000
Interest rate of notes payable						5.00%
Conversion price (in dollars per share) | $ / shares						$ 5.00
Debt instrument, term						5 years
Minimum conversion notice (in days)						30 days
Maximum conversion notice (in days)						60 days
Remaining principal									68,275,000	65,525,000
2023 Convertible Notes | Convertible Debt | Subsequent Event
Debt Instrument [Line Items]
Convertible debt, stock price trigger threshold (as a percent)	25.00%
Conversion price (in dollars per share) | $ / shares	$ 1.66
Debt instrument, convertible, days of volume weighted average price	10 days
BioReference Laboratories, Inc.
Debt Instrument [Line Items]
Net assets									608,600,000
Goodwill									283,000,000
Intangible assets									187,900,000
GeneDx Holdings | Subsequent Event
Debt Instrument [Line Items]
Payments to acquire equity securities			$ 5,000,000
Investment owned, shares purchased (in shares) | shares			14,285,714
GeneDx Holdings | Common Class A | Subsequent Event
Debt Instrument [Line Items]
Price per share of common stock (in dollars per share) | $ / shares			$ 0.35
Parent Company
Debt Instrument [Line Items]
Investments									1,665,355,000	1,870,743,000
Loss on conversion of the 2025 Notes									0	11,111,000	$ 0
Equity									1,561,648,000	1,685,126,000
Payments of dividend									33,000,000	45,000,000
Parent Company | Cumulative Effect, Period of Adoption, Adjustment
Debt Instrument [Line Items]
Equity													21,600,000
Parent Company | Cumulative Effect, Period of Adoption, Adjustment | Retained Earnings
Debt Instrument [Line Items]
Equity													17,500,000
Parent Company | Cumulative Effect, Period of Adoption, Adjustment | Additional Paid-in Capital
Debt Instrument [Line Items]
Equity													$ (39,100,000)
Parent Company | Senior Notes
Debt Instrument [Line Items]
Remaining principal									$ 142,096,000	119,360,000
Parent Company | Senior Notes | Cumulative Effect, Period of Adoption, Adjustment | Accounting Standards Update 2020-06
Debt Instrument [Line Items]
Remaining principal										21,642,000
Parent Company | Convertible Senior Notes Due 2025 | Convertible Debt
Debt Instrument [Line Items]
Debt face amount					$ 200,000,000
Interest rate of notes payable					4.50%
Conversion ratio					0.2367424
Conversion price (in dollars per share) | $ / shares					$ 4.22
Equivalent redemption price (as a percent)					100.00%
Converted debt amount				$ 55,400,000
Shares issued on converted debt (in shares) | shares				19,051,270
Loss on conversion of the 2025 Notes										$ 11,100,000
Shares issuable under debt agreement (in shares) | shares					30,000,000
Decrease in shares issuable under debt agreement (in shares) | shares				8,105,175
Outstanding shares on converted debt (in shares) | shares									21,144,825	21,144,825
Proceeds one-time nominal fee									$ 300,000
Parent Company | Convertible Senior Notes Due 2025 | Convertible Debt | Redemption period one
Debt Instrument [Line Items]
Convertible debt, stock price trigger threshold (as a percent)					130.00%
Parent Company | Convertible Senior Notes Due 2025 | Convertible Debt | Redemption period two
Debt Instrument [Line Items]
Convertible debt, stock price trigger threshold (as a percent)					98.00%
Parent Company | Convertible Senior Notes Due 2025 | Convertible Debt | Redemption period three
Debt Instrument [Line Items]
Number of trading days | day									20
Number of consecutive trading days applicable conversion price | day									30
Convertible debt, stock price trigger threshold (as a percent)									130.00%
Equivalent redemption price (as a percent)									100.00%
Parent Company | Convertible Senior Notes Due 2025 | Convertible Debt | Minimum | Redemption period one
Debt Instrument [Line Items]
Number of trading days | day					20
Parent Company | Convertible Senior Notes Due 2025 | Convertible Debt | Minimum | Redemption period two
Debt Instrument [Line Items]
Number of trading days | day					5
Parent Company | Convertible Senior Notes Due 2025 | Convertible Debt | Maximum | Redemption period one
Debt Instrument [Line Items]
Number of consecutive trading days applicable conversion price | day					30
Parent Company | Convertible Senior Notes Due 2025 | Convertible Debt | Maximum | Redemption period two
Debt Instrument [Line Items]
Number of consecutive trading days applicable conversion price | day					5
Parent Company | Notes Due February 1, 2033 | Convertible Debt
Debt Instrument [Line Items]
Converted debt amount												$ 143,200,000
Parent Company | Notes Due February 1, 2033 | Convertible Debt | Equity securities
Debt Instrument [Line Items]
Shares issued on converted debt (in shares) | shares												21,539,873
Parent Company | Notes Due February 1, 2033 | Senior Notes
Debt Instrument [Line Items]
Debt face amount		$ 175,000,000
Interest rate of notes payable		3.00%
Equivalent redemption price (as a percent)		100.00%
Parent Company | Notes Due February 1, 2033 | Notes
Debt Instrument [Line Items]
Equivalent redemption price (as a percent)								100.00%
Debt repurchase amount																28,800,000
Remaining principal																$ 3,000,000
Parent Company | New Credit Agreement | Line of Credit | Revolving Credit Facility
Debt Instrument [Line Items]
Credit line capacity							$ 75,000,000
Remaining borrowing capacity									$ 16,800,000
Long-term line of credit, noncurrent									18,100,000	$ 0
Parent Company | New Credit Agreement | Line of Credit | Revolving Credit Facility | 50% Or More Of Revolving Commitment
Debt Instrument [Line Items]
Commitment fee (as a percent)							0.375%
Parent Company | New Credit Agreement | Line of Credit | Revolving Credit Facility | Less Than or Equal To 50% Of Revolving Commitment
Debt Instrument [Line Items]
Commitment fee (as a percent)							0.25%
Parent Company | New Credit Agreement | Line of Credit | Revolving Credit Facility | LIBOR
Debt Instrument [Line Items]
Basis spread on variable rate (as a percent)							2.50%
Parent Company | New Credit Agreement | Line of Credit | Revolving Credit Facility | LIBOR, First 12 Months
Debt Instrument [Line Items]
Basis spread on variable rate (as a percent)							0.75%
Parent Company | New Credit Agreement | Line of Credit | Revolving Credit Facility | LIBOR, First 12 Months, Adjusted for Eurocurrency Liabilities
Debt Instrument [Line Items]
Basis spread on variable rate (as a percent)							1.75%
Parent Company | New Credit Agreement | Line of Credit | Swingline
Debt Instrument [Line Items]
Credit line capacity							$ 20,000,000
Parent Company | New Credit Agreement | Line of Credit | Letter of Credit
Debt Instrument [Line Items]
Credit line capacity							$ 20,000,000
Parent Company | 2023 Convertible Notes | Convertible Debt | Subsequent Event
Debt Instrument [Line Items]
Conversion price (in dollars per share) | $ / shares	$ 1.66
Debt Instrument, Convertible, Conversion Premium	25.00%
Parent Company | BioReference Laboratories, Inc.
Debt Instrument [Line Items]
Net assets									608,600,000
Goodwill									283,000,000
Intangible assets									$ 187,900,000
Percentage of net assets									25.00%
Restricted net assets									$ 1,600,000,000
Parent Company | GeneDx Holdings | Subsequent Event
Debt Instrument [Line Items]
Payments to acquire equity securities			$ 5,000,000
Investment owned, shares purchased (in shares) | shares			14,285,714
Parent Company | GeneDx Holdings | Common Class A | Subsequent Event
Debt Instrument [Line Items]
Price per share of common stock (in dollars per share) | $ / shares			$ 0.35